RxDoctor Payments Data

Jeanne Jagodzinski

Psychiatric/Mental Health · Fort Myers, FLNPI 1124320734

Payments from drug & device makers

$3,757in general payments, 2019–2025

Across 226 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759
  • Teva Pharmaceuticals USA, Inc.$605
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$539
  • Alkermes, Inc.$471
  • Otsuka America Pharmaceutical, Inc.$350
  • Johnson & Johnson$327
  • plus $705 from 10 others

What the payments were for

  • Food & beverage$3,61396%
  • Education$1444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,757 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$16,479
Medicare patients
73
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate89$260,322
VraylarCariprazine Hcl85$144,184
AustedoDeutetrabenazine14$134,751
Abilify MaintenaAripiprazole44$126,959
CaplytaLumateperone Tosylate24$40,106
Risperdal ConstaRisperidone Microspheres16$21,524
RexultiBrexpiprazole13$20,547
Aripiprazole198$19,495
Paliperidone ErPaliperidone28$10,988
Quetiapine Fumarate204$7,886
Ziprasidone Hcl82$6,851
Oxcarbazepine128$5,599
Olanzapine218$5,497
Trazodone Hcl255$5,470
Hydroxyzine Hcl162$5,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$327$281,846105 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$350$147,50657 claims
AbbVieVraylar$759$144,18485 claims
Teva Pharmaceuticals USA, Inc.Austedo$605$134,75114 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$539$40,10624 claims
Almatica Pharma LLCSertraline Hcl$44$2,002275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →